391 related articles for article (PubMed ID: 24431097)
1. A series of pharmacokinetic studies of ceftaroline fosamil in select populations: normal subjects, healthy elderly subjects, and subjects with renal impairment or end-stage renal disease requiring hemodialysis.
Riccobene T; Jakate A; Rank D
J Clin Pharmacol; 2014 Jul; 54(7):742-52. PubMed ID: 24431097
[TBL] [Abstract][Full Text] [Related]
2. An open-label, non-randomised, phase 1, single-dose study to assess the pharmacokinetics of ceftaroline in patients with end-stage renal disease requiring intermittent haemodialysis.
Sunzel M; Learoyd M; Li J; Li Y; Ngo N; Edeki T
Int J Antimicrob Agents; 2015 Dec; 46(6):682-8. PubMed ID: 26545441
[TBL] [Abstract][Full Text] [Related]
3. Population pharmacokinetics of ceftaroline in patients with acute bacterial skin and skin structure infections or community-acquired bacterial pneumonia.
Van Wart SA; Forrest A; Khariton T; Rubino CM; Bhavnani SM; Reynolds DK; Riccobene T; Ambrose PG
J Clin Pharmacol; 2013 Nov; 53(11):1155-67. PubMed ID: 23907740
[TBL] [Abstract][Full Text] [Related]
4. Ceftaroline fosamil: a new broad-spectrum cephalosporin.
Laudano JB
J Antimicrob Chemother; 2011 Apr; 66 Suppl 3():iii11-8. PubMed ID: 21482565
[TBL] [Abstract][Full Text] [Related]
5. Ceftaroline fosamil: a cephalosporin with activity against methicillin-resistant Staphylococcus aureus.
Poon H; Chang MH; Fung HB
Clin Ther; 2012 Apr; 34(4):743-65. PubMed ID: 22444785
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetic/pharmacodynamic analysis to evaluate ceftaroline fosamil dosing regimens for the treatment of community-acquired bacterial pneumonia and complicated skin and skin-structure infections in patients with normal and impaired renal function.
Canut A; Isla A; Rodríguez-Gascón A
Int J Antimicrob Agents; 2015 Apr; 45(4):399-405. PubMed ID: 25700566
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetic and pharmacodynamic evaluation of ceftaroline fosamil.
Merker A; Danziger LH; Rodvold KA; Glowacki RC
Expert Opin Drug Metab Toxicol; 2014 Dec; 10(12):1741-50. PubMed ID: 25347329
[TBL] [Abstract][Full Text] [Related]
8. Integrated safety summary of CANVAS 1 and 2 trials: Phase III, randomized, double-blind studies evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections.
Corrado ML
J Antimicrob Chemother; 2010 Nov; 65 Suppl 4():iv67-iv71. PubMed ID: 21115456
[TBL] [Abstract][Full Text] [Related]
9. Ceftaroline: a new cephalosporin with activity against resistant gram-positive pathogens.
Steed ME; Rybak MJ
Pharmacotherapy; 2010 Apr; 30(4):375-89. PubMed ID: 20334458
[TBL] [Abstract][Full Text] [Related]
10. Single-dose pharmacokinetic studies of abiraterone acetate in men with hepatic or renal impairment.
Marbury T; Lawitz E; Stonerock R; Gonzalez M; Jiao J; Breeding J; Haqq C; Verboven P; Stieltjes H; Yu M; Molina A; Acharya M; Chien C; Tran N
J Clin Pharmacol; 2014 Jul; 54(7):732-41. PubMed ID: 24374856
[TBL] [Abstract][Full Text] [Related]
11. Ceftaroline fosamil for treatment of community-acquired pneumonia: findings from FOCUS 1 and 2 and potential role in therapy.
DiMondi VP; Drew RH; Chen LF
Expert Rev Anti Infect Ther; 2011 Aug; 9(8):567-72. PubMed ID: 21819323
[TBL] [Abstract][Full Text] [Related]
12. Ceftaroline fosamil: a novel broad-spectrum cephalosporin with expanded anti-Gram-positive activity.
Biek D; Critchley IA; Riccobene TA; Thye DA
J Antimicrob Chemother; 2010 Nov; 65 Suppl 4():iv9-16. PubMed ID: 21115457
[TBL] [Abstract][Full Text] [Related]
13. Integrated safety summary of FOCUS 1 and FOCUS 2 trials: Phase III randomized, double-blind studies evaluating ceftaroline fosamil for the treatment of patients with community-acquired pneumonia.
Rank DR; Friedland HD; Laudano JB
J Antimicrob Chemother; 2011 Apr; 66 Suppl 3():iii53-9. PubMed ID: 21482570
[TBL] [Abstract][Full Text] [Related]
14. Ceftaroline Dosage Optimized for Pediatric Patients With Renal Impairment Using Physiologically Based Pharmacokinetic Modeling.
Zhou J; You X; Guo G; Ke M; Xu J; Ye L; Wu W; Huang P; Lin C
J Clin Pharmacol; 2021 Dec; 61(12):1646-1656. PubMed ID: 34329494
[TBL] [Abstract][Full Text] [Related]
15. The use of extrapolation based on modeling and simulation to support high-dose regimens of ceftaroline fosamil in pediatric patients with complicated skin and soft-tissue infections.
Chan PLS; McFadyen L; Quaye A; Leister-Tebbe H; Hendrick VM; Hammond J; Raber S
CPT Pharmacometrics Syst Pharmacol; 2021 Jun; 10(6):551-563. PubMed ID: 33687148
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetic and Pharmacodynamic Target Attainment in Adult and Pediatric Patients Following Administration of Ceftaroline Fosamil as a 5-Minute Infusion.
Riccobene TA; Carrothers TJ; Knebel W; Raber S; Chan PLS
Clin Pharmacol Drug Dev; 2021 Apr; 10(4):420-427. PubMed ID: 33465279
[TBL] [Abstract][Full Text] [Related]
17. FOCUS 1: a randomized, double-blinded, multicentre, Phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia.
File TM; Low DE; Eckburg PB; Talbot GH; Friedland HD; Lee J; Llorens L; Critchley IA; Thye DA;
J Antimicrob Chemother; 2011 Apr; 66 Suppl 3():iii19-32. PubMed ID: 21482566
[TBL] [Abstract][Full Text] [Related]
18. Ceftaroline: a novel broad-spectrum cephalosporin with activity against meticillin-resistant Staphylococcus aureus.
Zhanel GG; Sniezek G; Schweizer F; Zelenitsky S; Lagacé-Wiens PR; Rubinstein E; Gin AS; Hoban DJ; Karlowsky JA
Drugs; 2009; 69(7):809-31. PubMed ID: 19441869
[TBL] [Abstract][Full Text] [Related]
19. Review of ceftaroline fosamil microbiology: integrated FOCUS studies.
Critchley IA; Eckburg PB; Jandourek A; Biek D; Friedland HD; Thye DA
J Antimicrob Chemother; 2011 Apr; 66 Suppl 3():iii45-51. PubMed ID: 21482569
[TBL] [Abstract][Full Text] [Related]
20. Ceftaroline fosamil: drug profile and clinical data.
Kanafani ZA
Future Microbiol; 2011 Jan; 6(1):9-18. PubMed ID: 21162631
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
